Authors
Anita Soboń, Elżbieta Iskierka-Jażdżewska, Joanna Drozd-Sokolowska, Anna Puła, Małgorzata Gajewska, Michał Danecki, Łukasz Bołkun, Agata Ogłoza-Puchowska, Marta Morawska, Janusz Halka, Edyta Subocz, Agnieszka Podgórska, Jagoda Tryc-Szponder, Ewa Paszkiewicz-Kozik, Leszek Czernik, Anna Kopinska, Justyna Rybka, Agnieszka Szymczyk, Kamil Wdowiak, Paweł Steckiewicz, Aleksandra Gołos, Iwona Hus, Krzysztof Jamroziak, Tadeusz Robak, Ewa Lech-Maranda, Bartosz Puła
Published in
Leukemia & lymphoma. Pages 1-10. Aug 10, 2026. Epub Aug 10, 2026.
Abstract
We collected clinical data on 363 patients with relapsed/refractory chronic lymphocytic leukemia (RR-CLL) treated with venetoclax-rituximab (VR) in a real-world setting. The median age was 69.5 years (range, 32.5-91.6 years), and the median number of prior lines of therapy was 2 (range, 1-10). Fifty-three recipients (53/362, 13.8%) had previously received BTKi. The median follow-up was 22.8 months. The overall response rate was 97.1%. The median PFS and OS were not reached. The estimated 3 y-PFS rate was 62.1% (95% CI 54.9-70.2), and the 3 y-OS rate was 69.0% (95% CI 62.3-76.4). Eighty-five (23.5%) patients had completed their therapy, while 106 (29.4%) discontinued prematurely. Reasons for therapy discontinuation included mainly patients' death (n = 36, 34%) and cytopenias (n = 17,16.0%). Treatment outcomes with the VR regimen in a real-life setting were slightly worse than those reported in the MURANO trial, likely due to the inclusion of patients with advanced ECOG and prior BTKi treatment.
PMID:
42572902
Bibliographic data and abstract were imported from PubMed on 10 Aug 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 4
- Comments 0